From: A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
Condition | CAR | Target locus (knocked out) | Study model | Ref |
---|---|---|---|---|
TALEN | ||||
MM | BCMA | CD20 | MM.1S cell line NSG mice | [129] |
B-ALL | CD19 | TRAC CD52 | NSG mice | |
BL | CD22 | TRAC CD25 PD-1 | RAJI cell line NSG mice | [132] |
T-ALL | CD3 | TRAC | Jurkat cell line NSG mice | [133] |
B-ALL | CD20 | TRAC PD-1 | Cell line | [134] |
BL | CD22 | GM-CSF | RAJI and Daudi cell line | [135] |
B-ALL | CD19 | TRAC CD52 | NALM6 cell line NSG mice | [136] |
ZFN | ||||
B-ALL CLL MCL | CD19 | TRAC | Primary tumor cells | [126] |
B-ALL | CD19 | TRAC | Cell line | [7] |